EDEN PRAIRIE, Minn., (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the commencement of a collaborative effort with Dr. Mark Slaughter and the University of Louisville to study the impact of the C-Pulse technology on the pulmonary circulation and right heart, specifically in the field of pulmonary hypertension and heart failure.

Pulmonary arterial hypertension (PAH) is a debilitating condition characterized by progressive increases in pulmonary vascular resistance and loss of elasticity of the pulmonary artery and large vessels. Patients with PAH suffer from poor quality of life, shortness of breath and greatly reduced functional capacity leading to right ventricular dysfunction and ultimately, right heart failure. PAH afflicts approximately 200,000 patients worldwide and places a significant burden on the healthcare system, with limited treatment options available and 5 year survival rates as low as 34%¹. PAH and right heart failure are also commonly associated with left heart failure. Approximately 50% of patients with systolic heart failure or preserved ejection fraction heart failure (HFpEF) have PAH with similar 5 year outcomes². PAH and right heart failure also continue to remain a significant risk in the left ventricular assist device patient population³.These studies hope to provide scientific rationale for a new application of current C-Pulse therapy by leveraging the existing technology to apply counterpulsation to the pulmonary artery in acute and chronic animal preparations. Biochemical, neurohormonal and pressure-volume data will be used to assess the effects of C-Pulse on pulmonary circulation and right and left heart properties. A fully implantable system may provide therapeutic options in HFpEF population with PAH where there are currently no approved treatments.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

1. D’Alonzo, GE et al. Ann Int Med 115: 342-349, 1991
2. Miller WL et al. JACC HF 1(4): 290-299, 2013; Guazzi M. Circ. Heart Fail. 7: 367-377, 2014
3. MacGowan, GA and Schueler, S. Curr Opin Cardiol 27(3); 296-300. 2012

EDEN PRAIRIE, Minn., (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (NASDAQ:SSH) is pleased to announce the US Food and Drug Administration (FDA) has approved an amendment to the stopping rule criteria for the Company’s COUNTER HF™ pivotal study for its C-Pulse Heart Assist System®. The Agency has agreed to change this protocol from “all cause” deaths to specifically, mortality associated with device, procedure or therapy.

“Redefining COUNTER HF’s stoppage rule to be focused purely on C-Pulse related events is an important study protocol amendment as it greatly reduces our risk of having to pause the trial again due to unrelated C-Pulse mortality events,” commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.

Sunshine Heart previously announced on March 6, 2015 a temporary enrollment pause in accordance with the study’s original “stopping rule.” This particular protocol indicated that, in the event more than three of the first twenty subjects pass away for any reason, including non-device related deaths, the Company would work with the FDA to establish a plan before resuming enrollment. An independent Clinical Events Committee (CEC) determined that all four of the reported deaths were adjudicated as being non-device related and, on May 26th, the Company announced the FDA’s approval to resume enrollment in the COUNTER HF study.

Moving forward, the “stopping rule” has been amended such that COUNTER HF will be halted if more than seven of the first twenty implanted subjects pass away during device support within twelve months of implant. Importantly, in order for a study pause to occur, each mortality event will have to be adjudicated as possibly or definitely related to the procedure, therapy or device.

Individuals who are interested in exploring if they might qualify for COUNTER HF can visit www.HFClinicalStudy.com or call 1-888-978-8391.

About the COUNTER HF and OPTIONS HF Studies:

COUNTER HF is a prospective, randomized, multi-center clinical study. It is being conducted by heart failure and cardiac surgeon specialists in the United States. It is expected to randomize 388 patients in up to 40 clinical sites. The purpose of the study is to determine whether the C-Pulse System is a safe and effective treatment for heart failure patients who meet the following key study qualifications:

• NYHA Class III or early Class IV heart failure*;
• Ejection fraction ≤ 35% (measure of how well the heart pumps blood);
• Taking appropriate heart failure medications as prescribed by doctor; and
• Have been evaluated for cardiac resynchronization therapy with or without defibrillation (CRT, CRT-D) or implantable cardioverter defibrillator (ICD) therapy.

*New York Heart Class (NYHA) Class III or early Class IV: Very limited in daily activities or unable to do activities without discomfort. Become tired, short of breath, and have heart palpitations during physical activity. Note: Other qualifications apply and study doctors will determine who is eligible for the study.

OPTIONS HF is a post-market, multi-center, prospective, open label study that will include 50 patients in up to 15 European centers. The study is designed to observe clinical outcomes of heart failure patients treated with the C-Pulse system. The primary endpoint is comparable to the COUNTER HF study as it evaluates the rate of re-hospitalization due to worsening heart failure and heart failure related death in addition to many other traditional heart failure endpoints.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF™ US Pivotal Study for C-Pulse® Heart Assist System

“Resuming enrollment in COUNTER HF has been our top priority and was accomplished within the timelines originally announced. The proposed protocol modifications have enhanced an already robust protocol, and should increase the likelihood of success. We are encouraged by our investigators’ enthusiasm as witnessed by the high site representation at our recent investigator meeting,” commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.

Earlier in February 2015 the FDA unconditionally approved an interim analysis for the COUNTER HF study, as a means to potentially reduce the approval timeline for the C-Pulse therapy. FDA approval to resume study enrollment will now allow the Company to progress expeditiously towards that goal.

Individuals who are interested in exploring if they might qualify for COUNTER HF can visit www.HFClinicalStudy.com or call 1-888-978-8391.

About the COUNTER HF and OPTIONS HF Studies:

COUNTER HF is a prospective, randomized, multi-center clinical study. It is being conducted by heart failure and cardiac surgeon specialists in the United States. It is expected to randomize 388 patients in up to 40 clinical sites. The purpose of the study is to determine whether the C-Pulse System is a safe and effective treatment for heart failure patients who meet the following key study qualifications:

• NYHA Class III or early Class IV heart failure*;
• Ejection fraction ≤ 35% (measure of how well the heart pumps blood);
• Taking appropriate heart failure medications as prescribed by doctor; and
• Have been evaluated for cardiac resynchronization therapy with or without defibrillation (CRT, CRT-D) or implantable cardioverter defibrillator (ICD) therapy.

*New York Heart Class (NYHA) Class III or early Class IV: Very limited in daily activities or unable to do activities without discomfort. Become tired, short of breath, and have heart palpitations during physical activity. Note: Other qualifications apply and study doctors will determine who is eligible for the study.

OPTIONS HF is a post-market, multi-center, prospective, open label study that will include 50 patients in up to 15 European centers. The study is designed to observe clinical outcomes of heart failure patients treated with the C-Pulse system. The primary endpoint is comparable to the COUNTER HF study as it evaluates the rate of re-hospitalization due to worsening heart failure and heart failure related death in addition to many other traditional heart failure endpoints.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

Siemens Healthcare Diagnostics, Inc. (“Siemens”) today announced the full commercial launch of the Xprecia Stride™  Coagulation Analyzer following successful completion of its limited European release. The system will now be marketed through Siemens’ extensive sales and distribution network in a growing number of markets, currently excluding the U.S. (which will require FDA 510(k) clearance).

In addition, Siemens has today announced that the Xprecia Stride™  Coagulation Analyzer has been awarded the internationally respected Red Dot Award for Product Design for 2015. The Red Dot Product Design Competition started in Germany in 1954 and its award, the ‘Red Dot,’ is an internationally recognised quality seal. See www.red-dot.org for further details on the Red Dot competition and the award.

The Xprecia Stride™  Coagulation Analyzer delivers hand-held Prothrombin time testing (PT/INR) for point of-care monitoring and management of the oral anticoagulation therapy (OAT), Warfarin. The product was specifically designed to meet the growing demand for fast and reliable PT/INR results in physician offices and walk-in clinics to help healthcare professionals make informed decisions about patient care. Universal Biosensors will be the manufacturer of PT/INR strips for Siemens at the Company’s plant in Rowville, Victoria.

“The Xprecia Stride™ Coagulation Analyzer is among the most radical, user-friendly redesigns of a point of-care coagulation analyzer since they became widely available more than 20 years ago. This analyzer includes a number of innovations and features not found on most other point-of-care analyzers,” said David Stein, Ph.D., CEO of Siemens Diagnostics Point of Care Business Unit.

A copy of the press release by Siemens is attached.

UBI CEO Paul Wright said: “We are thrilled that the limited release has gone well and that Siemens will now be rolling out the Xprecia Stride™  Coagulation Analyzer. The Red Dot Award is a clear validation of the product’s unique features that will deliver real benefits to patients and healthcare professionals.”

The limited European release of the Xprecia Stride™  Coagulation Analyzer was initiated in December 2014.

Patients using Warfarin require frequent testing to assess the clotting tendency of their blood. The Prothrombin time (PT/INR) test allows physicians to adjust patient doses for diet and lifestyle changes. The worldwide point-of-care coagulation testing market was estimated at about US$1 billion in 2014 and is forecast to grow by about 9% per annum to about US$1.4 billion by 2018. The point-of-care coagulation testing market is dominated by PT/INR testing, which represents about 65% of this market.

Sunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal Trial of C-Pulse® Heart Assist System

EDEN PRAIRIE, Minn.,  (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) today announced it has received unconditional approval from the FDA to conduct an interim analysis of COUNTER HF, the Company’s U.S. pivotal study. The COUNTER HF study is a prospective, randomized, multi-center, controlled study that evaluates the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse’s unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure.

“Today’s announcement is a significant achievement for the company as it offers the potential to dramatically reduce the development timeline for this important solution for heart failure. The FDA decision to approve this interim analysis is not only unconditional but also arrives earlier than the originally anticipated timeframe of end Q1 2015. We are grateful for the FDA’s rapid response to our submission and look forward to working with the Agency through the balance of the COUNTER HF study and on the development of the next generation, fully implantable C-Pulse system,” commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.

A key potential benefit of conducting the analysis is the prospect of reducing the overall duration of the study should COUNTER HF meet the higher statistical threshold of the interim analysis. The study is a prospective, randomized, multi-center clinical trial. It is being conducted by heart failure and cardiac surgeon specialists in the United States. It is expected to randomize 388 patients in up to 40 clinical sites. The purpose of the study is to determine whether the C-Pulse System is a safe and effective treatment for heart failure patients who meet the following key study qualifications:

• NYHA Class III or early Class IV heart failure*;
• Ejection fraction ≤ 35% (measure of how well the heart pumps blood);
• Taking appropriate heart failure medications as prescribed by doctor; and
• Have been evaluated for cardiac resynchronization therapy with or without defibrillation (CRT, CRT-D) or implantable cardioverter defibrillator (ICD) therapy.

*New York Heart Class (NYHA) Class III or early Class IV: Very limited in daily activities or unable to do activities without discomfort. Become tired, short of breath, and have heart palpitations during physical activity. Note: Other qualifications apply and study doctors will determine who is eligible for the study.

Individuals who are interested in learning more about the trial and if they might qualify for the study can visitwww.HFClinicalStudy.com or call 1-888-978-8391.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

Robust pipeline places company in position to be among top seven US companion animal veterinary pharmaceutical companies by 2020

GREENSBORO, N.C., –Piedmont Animal Health announces its second approval from the Food and Drug Administration for companion animals, new advantusTM (imidacloprid) soft chew, an oral flavored chewable flea medication for dogs.i The new animal drug application (NADA) is formulated in Piedmont’s patented soft chew invention, offering convenient, palatable dosing. The approval represents the second FDA approval for Piedmont and its first NADA approval. In June 2013, Piedmont announced the approval of quellinTM (carprofen) soft chews, an abbreviated new animal drug application (ANADA).ii

Rapid Product Development
“From start to finish, this product was developed on a rapid timeline, thanks to our talented and experienced team of professionals,” says Roland Johnson, Piedmont founder and CEO. “With more than 20 additional products in various stages of development, we expect a steady stream of new product approvals–some of which we project will be blockbusters once they are in the marketplace.”

Top Seven by 2020
Piedmont plans to commercialize more than 10 of its pipeline products, and, as with advantus, already holds out-licensing agreements with multiple global animal health pharmaceutical companies for the others. Based on independent market research, sales of Piedmont’s retained portfolio products are projected to reach $175 million annually by the end of 2020.iii “With a pipeline this rich, I fully anticipate that Piedmont will be among the top seven companion animal veterinary pharmaceutical companies in the U.S. in just over five years,” adds Johnson.

About Piedmont Animal Health
Piedmont Animal Health (part of Piedmont Pharmaceuticals) is led by a team of seasoned veterinary pharmaceutical innovators that has developed, launched, or marketed more than 20 companion animal health products. Today, these products represent approximately 25 percent of the total revenue in the U.S. small animal veterinary segment. A leader in innovation, Piedmont is dedicated to developing products that improve compliance and ease of use. For more information, visit PiedmontAnimalHealth.com and PiedmontPharma.com

i NADA 141-435, Approved by FDA
ii ANADA 200-555, Approved by FDA
iii Based on independent new product research conducted by AllPoints Research with 316 veterinary practices in Nov/Dec 2014

Universal Biosensors, Inc. (ASX: UBI) is pleased to announce that Siemens Healthcare Diagnostics Inc. (“Siemens”) has initiated the European limited release of the Xprecia Stride™ Coagulation Analyzer, its first point-of-care coagulation testing product. The Xprecia Stride™ Coagulation Analyzer is a PT-INR testing system that incorporates UBI’s unique electrochemical sensing technology which offers high performance and ease-of-use in an affordable, handheld format. The product launch has triggered a milestone payment of US$1 million from Siemens to Universal Biosensors.

Universal Biosensors CEO Paul Wright said: “This is an important milestone for both Universal Biosensors and Siemens. We have been collaborating on the development of this product for more than three years and we are confident the Xprecia Stride™ Coagulation Analyzer will be well received in the point-of-care market.”

The system is used to monitor the application of the anti-coagulant therapy, Warfarin. Universal Biosensors is the exclusive manufacturer of PT-INR strips for Siemens at the Company’s existing plant in Rowville, Victoria.

It is estimated that up to ten million patients globally are taking Warfarin. Patients are prescribed the drug for a variety of reasons, including the treatment of blood clots in the veins or certain heart conditions which increase the likelihood of a potentially life-threatening clot forming. Patients on Warfarin require frequent testing to assess the clotting tendency of their blood. The Prothrombin Time (PT-INR) test allows physicians to adjust patient doses for diet and lifestyle changes.

The worldwide point-of-care coagulation testing market was estimated at ~US$1.0 billion in 2014 and is forecast to grow by ~9% per annum to ~US$1.4 billion by 2018.1 The coagulation testing market is dominated by PT-INR testing, which represents about 65% of this market. There are currently two major players in the POC Professional PT-INR testing market – Roche and Alere. The Xprecia Stride™ Coagulation Analyzer will represent Siemens’ first entry into this market.

On 9 December, UBI announced that the product had completed CE mark self-certification. The PT-INR test is the first of several tests in development with Siemens designed to bring laboratory-quality to the point-of-care.

CEO of Siemens Healthcare Point-of-Care business unit, Dr. David Stein said: “The Xprecia Stride™ Coagulation Analyzer is an exciting new product in an attractive market space for Siemens, extending our 30 years of leadership in hemostasis now to the point-of-care. Our teams have worked hard together to reach this important milestone in our collaboration which offers great opportunity to bring laboratory performance to near-patient testing.”

9 December 2014

Universal Biosensors, Inc. (ASX: UBI) is pleased to announce that Siemens Healthcare Diagnostics Inc. (“Siemens”) has received CE Mark approval for the Xprecia Stride™ Coagulation Analyzer, the first point-of-care coagulation analyzer developed in collaboration with Universal Biosensors.

The Xprecia Stride™ Coagulation Analyzer is a prothrombin time (PT-INR) testing system used to monitor the application of the anti-coagulant therapy, Warfarin. Universal Biosensors will exclusively manufacture PT-INR strips for Siemens at the Company’s existing plant in Rowville, Victoria.

The CE marking follows the receipt of two commercial orders from Siemens for the production and supply of PT-INR test strips by Universal Biosensors, and is the final step prior to product launch in Europe.

The CE marking is mandatory for any company prior to selling its product within the 31 countries operating in the European Economic Area. The CE marking indicates a product is fully compliant with all relevant EU legislation and can move freely within the European Economic Area.

It is estimated about ten million patients globally are taking Warfarin. Patients are prescribed the drug for a variety of reasons, including the treatment of blood clots in the veins or certain heart conditions which increase the likelihood of a potentially life-threatening clot forming. Patients on Warfarin require frequent testing of the clotting tendency of their blood. PT-INR testing allows physicians to adjust patient doses for diet and lifestyle changes.

According to recent research, the worldwide point-of-care coagulation testing market was estimated at around US$1.0 billion in 2014 and is forecast to grow by 9% per annum to US$1.4 billion by 2018.1 The coagulation testing market is dominated by PT-INR testing, which represents about 65% of this market.

Universal Biosensors CEO Paul Wright said: “Receipt of the CE marking is an important step prior to the market launch of this exciting new coagulation testing product developed in partnership with Siemens. We are looking forward to the launch of this new device and continue to work with Siemens to bring powerful and innovative systems to point-of-care testing.”

Enquiries:
Mr Paul Wright: 03 9213 9000
1 Espicom, “The Cardiology Point-of-Care Diagnostics Market to 2018”, July 2014

About Universal Biosensors
For additional information in relation to Universal Biosensors, refer to
http://www.universalbiosensors.com.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements
The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.

Austrian Site Achieves First Implant

EDEN PRAIRIE, Minn., Dec. 1, 2014 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the Company’s initial Austrian site for the OPTIONS-HF study has implanted its first patient with the C-Pulse System for moderate to severe heart failure. Prof. Dr. Herwig Antretter of the University of Innsbruck performed the operation, which took place on November 11th, 2014. A 92 minute surgical implantation procedure was successfully completed and the patient was discharged from the hospital 7 days post-surgery. This milestone marks the eleventh implantation of the C-Pulse System across fourteen activated EU centers participating in the OPTIONS HF post-market surveillance clinical study.

“The C-pulse system is an ideal addition for patients in the treatment of NYHA III and ambulatory IV stage heart failure,” said Prof. Dr. Antretter. “It is easy to implant the device, doesn´t need a heart lung machine, and allows for quick patient recovery. Our patient was extubated in the operating room, stayed just a couple of hours in the ICU, and was then transferred to a normal ward. We discharged him after only one week.”

The patient was selected in cooperation with Univ.-Doz. Dr. Gerhard Poelzl, F.E.S.C. a leading Heart Failure Cardiologist (department of Univ. Prof. Wolfgang-M. Franz, Internal Medicine III, Cardiology and Angiology) in the University Hospital of Innsbruck. The patient suffers from dilated cardiomyopathy with severe impairment of his left ventricle, low ejection fraction (EF < 25%) and has survived an extensive cardiopulmonary resuscitation due to sudden cardiac arrest in January 2014 without any neurological deficit. Despite his advanced age and his medical history, the patient remains highly active and employed.

“I’m extremely pleased that we have introduced the C-Pulse therapy to yet another key country. As discussed in our Q3 quarterly update, we continue to remain enthusiastic regarding the increased overall momentum for the OPTIONS HF study,” commented Dave Rosa, Sunshine Heart Inc. Chief Executive Officer.

The OPTIONS HF study is a post-market, multi-center, prospective, open label study that will include 50 patients in up to 15 European centers. The study is designed to observe clinical outcomes of heart failure patients treated with the C-Pulse system. The primary endpoint is comparable to the COUNTER HF trial as it evaluates the rate of re-hospitalization due to worsening heart failure and heart failure related death in addition to many other traditional heart failure endpoints.

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine^® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

GREENSBORO, N.C.,  – Piedmont Pharmaceuticals, LLC, an innovative pharmaceutical company focused on veterinary market pharmaceuticals, today announced its hiring of Mr. Stan Cruitt as Vice President of Marketing Services. “We couldn’t be more pleased to have Stan join our team. His longstanding record of animal health pharmaceuticals launch success represents perfect timing as we at Piedmont are beginning to prepare for significant product launches,” said Roland Johnson, founder, CEO and Board member of Piedmont Pharmaceuticals. “His record on market and product evaluation, product positioning and communications/marketing strategies stands against the very best in the industry. Stan was honored as one of the top marketers in the US by Advertising Age and Newsweek after one of his major product launches”, adds Mr. Johnson.

Cruitt has held marketing, management and executive positions at Merck, Ciba and Novartis in the animal health industry and has been President and/or founder of three human healthcare startups. Cruitt is the latest addition to Piedmont’s growing cadre of industry leaders joining their management team. A team which now, in total, are responsible for the development and/or marketing and launch of many of the leading veterinary pharmaceuticals today; representing nearly a third of the total US sales dollars for the companion animal veterinary pharmaceutical industry.

“I’ve reviewed the Piedmont product development portfolio and can say with confidence that they have several products that will become the leader in their respective product categories in veterinary medicine” said Cruitt. “Each will be a prescription product and a valuable addition to the veterinarian’s treatment solution.”

“We have 25 new veterinary pharmaceutical products (New Animal Drug Application (NADA) and Abbreviated NADA (ANADA)) in various levels of development, with a steady stream of approvals expected annually through 2020,” adds Mr. Johnson.

About Piedmont Pharmaceuticals, LLC

Piedmont Pharmaceuticals, LLC, is an innovative development and marketing company focused on veterinary pharmaceuticals. Piedmont is a world-class animal health pharmaceutical company with an objective of being among the top seven largest companion animal pharmaceutical companies in the US by 2020. Towards accomplishing that goal, Piedmont is continuing to make significant progress with its current product development portfolio.

EDEN PRAIRIE, Minn., Aug. 19, 2014 (GLOBE NEWSWIRE) —

Sunshine Heart, Inc. (Nasdaq:SSH) today announced that the current condition of a heart failure patient implanted with the C-Pulse^® System improved after six weeks of treatment, allowing him to attend his daughter’s wedding. The patient, Ross Swift, a 54 year-old grandfather from Devon, U.K., received C-Pulse at Harefield Hospital in London and is participating in the OPTIONS HF study, a post-market surveillance study being conducted in countries in Western Europe. C-Pulse system received the CE Mark in 2012. The story was reported in an article published today in The Daily Mail, titled, Me and My Operation: Pump that squeezes your arteries to help fight heart failure. The surgical procedure was carried out by André Simon, M.D., director of transplantation at Royal Brompton & Harefield NHS Foundation Trust

“When I received the C-Pulse System, immediately I could tell there was a difference. When I breathed, it felt clearer. I had more color in my face and my family said my attitude changed,” said Mr. Swift. “I feel more positive. I find day-to-day activities, which used to wear me out, much easier to get on with and recover from afterwards.

“The wedding was amazing. Everybody was crying knowing what we had been through. Walking my daughter down the aisle was something a few months ago we didn’t believe was possible.”

The C-Pulse System’s design is based on an extra-aortic balloon cuff counter-pulsation therapy that is applied outside of the bloodstream and assists the heart by reducing the workload of the left ventricle. During inflation of the balloon cuff, blood flow is increased to the coronary arteries, thereby providing additional oxygen which is vital to a failing heart. During deflation of the balloon cuff, the workload or pumping required by the left ventricle is reduced. The balloon’s inflation and deflation is synchronized to the patient’s heart rhythm, similar to a pacemaker.

“The C-Pulse System is a treatment option that has not previously been available for this particular group of heart failure patients,” said Dr. Simon “The aim of implanting the system is to help slow the deterioration of a failing heart, which can relieve heart failure symptoms and improve their quality of life. At Harefield Hospital we see lots of patients with heart failure who are limited in their everyday activities, such as walking to the shops or taking part in family activities, but many of these patients are not sick enough to need a heart transplant.”

Sunshine Heart is currently enrolling patients in clinical studies in the U.S. and Europe for treatment of moderate to severe heart failure. The OPTIONS HF clinical study is a post-market, multi-center, prospective, surveillance study in up to fifteen European centers. The study is designed to observe long-term clinical outcomes of heart failure patients treated with the C-Pulse System. Concurrently, the company’s COUNTER HF™ US pivotal study is underway and designed to achieve commercial approval of the C-Pulse System in the United States.

More information regarding the US COUNTER™ HF clinical study can be found at: http://hfclinicalstudy.com/index.htm

More information regarding the European OPTIONS HF clinical study can be found at: http://clinicaltrials.gov/ct2/show/NCT01872949?term=NCT01872949&rank=1

August 8, 2014

Ross Swift said his life had improved, but he remains on the organ transplant list

A Devon man fitted with a new device aimed at supporting a failing heart, says it means he has “a life again”.

Ross Swift, 54, from Ivybridge, is believed to be the first UK patient to receive the Sunshine Heart implant, which helps reduce the organ’s pumping workload.

Mr Swift said the device meant he had was able to walk his daughter down the aisle at her wedding this month.

One expert said the device added a “tremendous amount of quality of life”.

During inflation of the balloon, blood flow is increased to the coronary arteries. The cuff then compresses and releases the aorta, helping the heart to function.

Although it requires the wearing of an external pack, Mr Swift said his new lease of life was not something he had not thought possible prior to having the device being fitted at the Royal Brompton & Harefield NHS Foundation Trust.

Mr Andre Simon, director of heart transplantation at the trust, said Mr Swift had been fitted with the device as part of a study.

He said: “It works in harmony with the heart … the heart gets more blood and it gets easier for the heart to work.”

Mr Swift said the device meant he was able to participate in the wedding of his daughter

Although Mr Swift remains on an organ transplant list, he said the device meant he was more mobile and able to join in the celebrations for his daughter Hayley’s wedding in Ugborough on 9 August.

He said: “I was just sick looking out of the window, watching the leaves fall, thinking: ‘This is it, I’ve not got long to go’.

“Now I’ve got a life again and, hopefully, a heart will come along in the next two years and I can start again.”

Mr Simon said: “It’s better than we expected or hoped.

“It may not prolong life, but it does add a tremendous amount of quality of life.”

Piedmont Pharmaceuticals Announces New Chairman of the Board

GREENSBORO, N.C., (July 15, 2014) – Piedmont Pharmaceuticals, LLC, an innovative specialty pharmaceutical company focused on animal health and human therapeutics, today announced its Board of Directors and shareholders have elected industry veteran Dennis Steadman chairman and member of the Board of Directors effective immediately.

“There is no better person than Dennis Steadman to help Piedmont Pharmaceuticals as we transition the company to a fully integrated research and development, marketing and sales pet health business,” said Roland Johnson, founder, CEO and member of the Board of Directors of Piedmont Pharmaceuticals, LLC. “His strategic vision, combined with operational experience ranging from capital funding and product development, to building and leading commercial organizations is exactly what Piedmont Pharmaceuticals needs as the company enters its next phase of growth.”

Steadman, an experienced animal health executive was the founder and CEO of Velcera, Inc., a pet health company that achieved sales of $60 million within the first year of launch and was acquired in 2013 for $160 million. Prior to Velcera, he held executive and consulting positions for more than 35 years, including Vice President, North American Operations and Global Management Committee Member with Merial Ltd., a leading global animal health company, multiple domestic, international and global executive positions with Merck animal health, and more than a decade with a consulting subsidiary of Chase Manhattan Bank. Steadman holds a master’s degree in Agricultural Economics and a bachelor’s degree in Business Management from Pennsylvania State University and has completed the Executive Program in Finance at the Harvard Business School.

“Piedmont has one of the largest and most impressive pet prescription product portfolios in the industry today including the first of its kind soft chew pet drug delivery platform,” said Dennis Steadman. “Piedmont has now built itself to the brink of breakthrough value and material industry impact and I look forward to helping accelerate the company’s success.”

About Soft Chew Formulation

In 2013, the US Food and Drug Administration’s Center for Veterinary Medicine approved Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. The flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category. The soft chew formulation provides pet owners with a convenient and friendly way to medicate dogs.

About Piedmont Pharmaceuticals, LLC
Piedmont Pharmaceuticals, LLC, is a strategic development and licensing company focused on animal health and human therapeutics with specific expertise in parasitology and drug delivery systems.

For more information visit http://www.piedmontpharma.com/OurCompany/

July 8, 2014

Context-Based Security and Advanced Fraud Prevention Provider Recognized for Tremendous Annual Growth and Recent Funding

San Jose, CA – July 8, 2014 – ThreatMetrix®, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced it has been recognized as one of the 2014 “Hottest Companies in Silicon Valley” by Lead 411.

Lead411’s “Hottest Companies in Silicon Valley” list recognizes privately held companies in the software, wireless, Internet, hardware and media industries within Silicon Valley. Each company must have either doubled its revenue over the past two years or received more than $5 million in funding in the past two years.

This list originally started with over 1816 companies and was narrowed down to the top 87.

“We’re thrilled to be recognized as one of the fastest-growing software companies in Silicon Valley,” said Bert Rankin, chief marketing officer, ThreatMetrix. “Our fraud and security solutions collect valuable information and provide real-time insights to protect against account takeover, payment fraud, fraudulent account registration and multi-channel Web fraud. As cybercriminals become increasingly sophisticated, businesses must leverage a collective network to protect against online threats and our recent round of funding serves as validation of the high level of trust in our solution.”

In March 2014 ThreatMetrix secured $20 million in Series E funding led by Adams Street Partners. Through theThreatMetrix® Global Trust Intelligence Network (The Network) – the world’s largest network of shared intelligence –ThreatMetrix is positioned to effectively protect businesses and individuals against cybercrime without disrupting the user experience. The Network enables businesses to share anonymized information across business boundaries to deliver the most comprehensive risk assessment in real-time.

“This year’s Hottest Silicon Valley Award winners are stronger than ever. We expect to see large growth and ‘big things’ from this group,” said Tom Blue, Lead411 CEO.

For a full list of winners, visit http://www.lead411.com/awards/2014/silicon-valley.html.

ThreatMetrix Resources

• Whitepaper: Combating Cybercrime – A Collective Global Approach
• CEO Blog Post: A New Model for Building Trust on the Internet

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix® Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

About Lead411
Lead411 provides information, news, and research about U.S. companies and their executives. Founded in 2001, its goal has been to focus on quality corporate data that is valid and useful rather than producing as many company records as possible. In addition, Lead411 tracks company news in order to alert its customers about venture financing, new hires, hiring plans, etc. Customers include Gartner, Administaff and ADP.

© 2014 ThreatMetrix. All rights reserved. ThreatMetrix, TrustDefender ID, TrustDefender Cloud, TrustDefender Mobile, TrustDefender Client, the TrustDefender Cybercrime Protection Platform, ThreatMetrix Labs, and the ThreatMetrix logo are trademarks or registered trademarks of ThreatMetrix in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Sunshine Heart Appoints Brian Brown as Senior Vice President of Operations and Technology

EDEN PRAIRIE, Minn., June 16, 2014 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) today announced the appointment of Brian Brown to the position of Senior Vice President of Operations and Technology. In this capacity, Mr. Brown will manage the Company’s R & D program for its flagship C-Pulse® Heart Assist System, a medical device addressing Class III and ambulatory Class IV heart failure. Additionally, Mr. Brown will be responsible for operations inclusive of internal and contracted manufacturing.

Mr. Brown comes to Sunshine Heart after serving as R & D, Vice President Cardiovascular at Boston Scientific for the past 10 years. Prior to joining Boston Scientific in 1994, he held multiple engineering and managerial roles at SciMED Life Systems Inc., a developer and marketer of medical devices used principally to treat cardiovascular disease which was acquired by Boston Scientific.

“Brian brings a broad range of experiences covering all aspects of transforming new technologies into marketable products. His specific role in leading the technology transition from an early stage development company to one of the largest cardiovascular device corporations in the world is extremely valuable to an emerging company such as Sunshine Heart,” said Dave Rosa, Chief Executive Officer of Sunshine Heart.

Mr. Brown has spent 24 years in the medical device industry including senior managerial roles at Boston Scientific where he most recently held the position of R & D, Vice President, Cardiovascular from 2004-2014, and SciMED Life Systems which was acquired by Boston Scientific in 1994. Boston Scientific is an international, publicly traded company headquartered in Boston, MA focused on the design, manufacture, and sale of minimally invasive medical devices in the areas of disposable devices (single use), permanent implants, and combination drug devices. The Interventional Cardiology business unit represents a $2B division of the company’s greater than $7B of annual revenue. As R & D, VP of Cardiovascular, Brian directed the multisite worldwide research and development activities for the accelerated multi-billion dollar launches of implantable stents, drug delivery technologies, disposable catheters and adjunctive devices. Mandates typically evolved from early exploratory work, to technology development projects, to product commercialization, followed by line extensions or sustaining activities. Brian holds a Bachelor of Science, Mechanical Engineering with an emphasis on electro -mechanical automation from North Dakota State University.

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine^® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Espoo, Finland – Nokia confirms that it has recently completed the acquisition of the Australian company Mesaplexx Pty Ltd in order to boost its radio capabilities in the Networks business. Mesaplexx has unique know-how in developing compact, high performance radio frequency (RF) filter technology for the mobile industry.

Nokia is continually improving its radio systems whilst making them smaller, lighter and more efficient. The Nokia Flexi family of radio access base stations offers cutting-edge solutions that balance energy efficiency, power output and form factor. Adding the very advanced Mesaplexx technology can enhance them further, potentially reducing small cells form factor by 30% or more.

Every base station needs RF filters, for example to ensure that spectrum can be shared within the same geographical area and that the same antenna can serve for both transmit and receive purposes. The Mesaplexx expertise could help improve radio performance, leading to higher capacity and more efficient networks. This technology would also help reduce overall cost and power consumption and keep radio signal loss to a minimum.

“Those familiar with radio technologies know that while there has been a lot of progress in recent years, filters are one area where new innovations can still yield significant improvements in performance,” said Marc Rouanne, executive vice president, Mobile Broadband at Nokia. “This company’s stand-out expertise has the potential to achieve that.”

With this transaction, Nokia continues to invest in technology innovation for the best mobile broadband experience.

About Nokia

Nokia invests in technologies important in a world where billions of devices are connected. We are focused on three businesses: network infrastructure software, hardware and services, which we offer through Networks; location intelligence, which we provide through HERE; and advanced technology development and licensing, which we pursue through Technologies. Each of these businesses is a leader in its respective field.

Through Networks, Nokia is the world’s specialist in mobile broadband. From the first ever call on GSM, to the first call on LTE, we operate at the forefront of each generation of mobile technology. Our global experts invent the new capabilities our customers need in their networks. We provide the world’s most efficient mobile networks, the intelligence to maximize the value of those networks, and the services to make it all work seamlessly. www.nsn.com / www.company.nokia.com

TrustDefender™ Cybercrime Protection Platform Recognized for Offering Unified Intelligence with Integrated Cybercrime Protection Platform

San Jose, CA – May 28, 2014 – ThreatMetrix®, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced that the TrustDefender™ Cybercrime Protection Platform won the Judges Choice for Best Overall Fraud/Security Solution at the 2014 CardNotPresent.com (CNP) Awards.

The CNP Award for Best Overall Fraud/Security Solution recognizes the provider that most efficiently reduced costs related to fraud in card-not-present transactions by identifying as much potential fraudulent activity as possible while enabling merchants to accept as many transactions as possible. The awards were announced during the CNP Expo, held May 19-22 in Orlando.

“Significant growth in e-commerce and mobile payments continues to spur innovation and excellence from the technology providers serving card-not-present merchants,” said CardNotPresent.com Founder & CEO Steve Casco. “That growth is reflected in this year’s CNP Awards, which had a record number of nominations and a record number of votes for Customer Choice nominees. The CNP Awards have become the standard by which companies, programs and services around the world are being recognized and judged now and in the future.”

The panel of five judges chose the TrustDefender Cybercrime Protection Platform because, in addition to taking the usual measures, including malware detection and device identification, to make e-commerce transactions secure, the platform detects fraud by analyzing online identities and their associated devices in real time to identify between authentic and fraudulent transactions.

“At ThreatMetrix, we constantly enhance our solutions to enable businesses to stay one step ahead of growing cybercrime threats,” said Bert Rankin, chief marketing officer, ThreatMetrix. “Between account takeover, payment fraud, identity spoofing and other threats, businesses need a way to quickly and efficiently identify suspicious behavior related to online transactions without driving away trusted customers. Our platform leverages the most comprehensive global data repository of fraud intelligence with unprecedented analytics to protect web and mobile-based e-commerce transactions.”

In 2013, ThreatMetrix launched several breakthrough technologies to support its platform, including ThreatMetrix™ Trust Tags and ThreatMetrix™ Persona ID. Trust Tags enable businesses to anonymously review and validate customer credentials and past behaviors to allow frictionless access while simultaneously preventing cybercrime. Additionally, Persona ID enables businesses to evaluate expected customer behavior based on industry standards. The platform was updated again in March 2014, with an extension that delivers sophisticated trust analytics through endpoint and context intelligence, as well as enhanced mobile location-based authentication and jailbreak detection.

The TrustDefender platform is built on the ThreatMetrix® Global Trust Intelligence Network (The Network), which profiles tens of millions of users and their devices every day to differentiate between authentic and suspicious transactions and online activity. The Network provides analytics in real time, evaluating logins, payments, new account registrations and remote access attempts.

To learn more about the ThreatMetrix TrustDefender Cybercrime Protection Platform, visithttp://www.threatmetrix.com/platform/trustdefender-cybercrime-protection-platform/.

ThreatMetrix Resources

• Whitepaper: Combating Cybercrime – A Collective Global Approach

• Webinar: The Cost to E-Commerce from Credit Card Data Breaches

• Datasheet: Eliminate Fraudulent Account Registration

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix® Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

By Giles Parkinson on 22 May 2014

A ground-breaking, $23.4 million project to cut out daytime diesel consumption at Rio Tinto bauxite mine at Weipa could unlock billions of dollars of similar investments in the mining industry – which is weighed down by soaring energy costs.

Mining giant Rio Tinto is to host a $23.4 million solar PV plus storage facility at its Weipa bauxite mine, that is the first of its type and scale in the world and could unleash billions of dollars of similar investment.

Rio Tinto Alcan – with the help of the Australian Renewable Energy Agency – is to install a 1.7MW solar PV array at its Weipa bauxite mine later this year, and then add a further 5MW of solar PV and battery storage.

The Weipa mine (pictured) is located on the Cape York Peninsula at the very northern tip of eastern Australia, and relies on expensive diesel that has to be shipped in.

The first phase of the solar project – to be built with First Solar thin-film modules and constructed by Australian solar firm Ingenero – is expected to reduce daytime diesel demand from the mine’s 26MW diesel generator by up to 20 per cent.

However, the addition of more solar and storage to balance out intermittency could reduce daytime diesel consumption altogether at certain times.

The Weipa project was the first of around 70 submissions  – worth several billion dollars of investment – from mining operators in Australia for funding for such ground breaking projects under ARENA’s $400 million remote energy program.

The ending of the commodities boom has made miners more focused on energy costs. Rio Tinto recently announced the closure of the Groote Eylandt mine in Northern Territory because it was being crushed by fuel costs. Solar and other technologies are now emerging as viable alternatives, even with the diesel excise exemption enjoyed by the mining industry.

ARENA, which has been marked for closure by Tony Abbott’s ultra conservative government in Australia, is committing $10.3 million over the two phases of the project.

ARENA CEO Ivor Frischknect said it is critical as part of a “show and tell” exercise that will help make miners understand the technology, accept its reliability, and identify where further cost cuts are made. This will lead to reduced costs in future projects, and ultimately remove the need for any government support.

“We need a few of these projects to show how cost-effective they can be,” Frischknecht told RenewEconomy.

“Transporting fuel long distances for generators is dangerous and subject to variable weather conditions – it is a costly, unpredictable arrangement that doesn’t make good economic sense.

“However, miners need to be confident about the integration of such technology, EPC contractors need to learn about the difficulties of delivering modules in such remote locations, and (sub contractors) don’t know yet what they don’t know.

“I think this is just the tip of the iceberg … energy security is a big deal for miners. ARENA sees mining as a huge potential off-grid user of renewable energy in Australia and congratulates Rio Tinto Alcan for paving the way for other mining operations to adopt renewable energy and offset diesel use through this landmark demonstration project.”

Whether ARENA gets to spend more on its remote mining energy program may depend on support in the Senate, which could reject the repeal bill being prepared by the Abbott government (which had made a pre-election promise to retain ARENA).

Frischknect said it was unclear how many such projects would need to be funded in such a way to unleash further unsubsidized investment from the mining community.  “There has been a lot of discussion about that, it could be that we need to sign on all the majors to enable the key internal decision-making.”

Jack Curtis, the head of business development for First Solar in Australia, says there has been a tipping point in the mining community in the last six months, where the big operators have realized that solar can provide an economic alternative to soaring diesel and gas prices.

“We think that this will show that solar can go mainstream,” Curtis said. He expected other large companies to follow, not just in Australia, but in other solar rich mining regions. “Rio Tinto wouldn’t be doing this if it was a one-off effort,” he said.

First Solar modules were used to construct Australia’s first utility-scale solar farm in Australia, the 10MW Greenough River project near Geraldton, and the largest solar farms under construction, the combined 153MW facilities at Broken Hill and Nyngan in NSW.

Miners in Chile have begun to install solar PV projects, and even Australia’s Fortescue Metals recently tendered for a 3MW solar PV project to help power its Christmas Creek mining camp at its large Cloudbreak iron ore mine in the Pilbara. BHP Billion considered a range of renewable technology options, including solar and geothermal, in planning for its now deferred expansion of the Olympic Dam mine in South Australia.

Other solar technologies, such as solar thermal with storage being developed by Solar Reserve and Australia’s Vast Solar, also see off-grid mining applications.

Gareth Manderson, the general manager of operations at Rio Tinto Alcan’s Weipa mine, said the hybrid diesel/PV solution will introduce to the site “a reliable source of electricity, with low maintenance requirements.”

The first phase of the project is scheduled to be completed later this year, with phase two set for 2017. Rio Tinto Alcan will buy the electricity under a 15-year power purchase agreement.

A total of 18,000 modules will be mounted on steel and aluminium structures in the first phase, generating  2,620MWh of electricity each year for use in the mine and the processing plant. The specifications of the storage component have yet to be worked out.

It is the first time in Australia that a mining company has adopted renewable energy to power a mining operation.

Rio Tinto said the 6.7 megawatt solar photovoltaic solar farm would provide power to the Rio Tinto Alcan Weipa bauxite mine, processing facilities as well as the township on the Western Cape York Peninsula.

“We expect the use of solar power will reduce Weipa’s annual carbon dioxide emissions by around 1600 tonnes,” a Rio Tinto Alcan official said.

First Solar and its partner, Queensland-based solar power company Ingenero, are investing $12.1 million in the project, with a total of $11.3 million conditionally committed by the Australian Renewable Energy Agency.

ARENA was set up by the Gillard government in 2012 to independently manage Australia’s renewable energy program. The Abbott government wants to abolish the agency but would need to pass a repeal Act through parliament.

An ARENA spokesman yesterday said projects with funding agreements in place with the agency “will not be affected by funding changes” in future and it “continues to be business as usual for ARENA”.

The project’s first stage will be completed in January, with 18,000 PV solar panels forming a 1.7 megawatt solar farm that will be supplemented by diesel generation.

By the end of stage two, the solar farm will also have battery storage, which will mean up to 100 per cent of diesel-generated electricity can be replaced by solar power.

Jack Curtis, First Solar’s vice president of business development for Asia-Pacific, said: “First Solar is delighted to be working with Rio Tinto, ARENA and Ingenero on this landmark project that demonstrates how solar PV can be used to power the resources sector.”

BRISBANE, Australia--(BUSINESS WIRE)--May 21, 2014--

First Solar, Inc. (NASDAQ: FSLR), Rio Tinto and Ingenero today announced that agreement has been reached for the development of the Weipa Solar Photovoltaic (PV) Project in Queensland, Australia. The project has received official confirmation of funding from the Commonwealth Government, with an initial commitment of $3.5 million from the Australian Renewable Energy Agency (ARENA) to be followed by an allocation of up to $7.8 million for the project’s second phase.

First Solar will leverage its expertise in utility-scale grid integration and plant control systems to offer a FuelSmart solution that provides maximum fuel savings while maintaining system reliability. Combined with Ingenero’s proven design, development and integration experience, the project will generate electricity for Rio Tinto Alcan’s (RTA) Weipa bauxite mine, processing facilities and township on the Western Cape York Peninsula.

“Rio Tinto Alcan is pleased to support the addition of renewable energy to complement the existing diesel generation at Weipa,” said RTA General Manager Weipa Operations Gareth Manderson. “We expect the use of solar power will reduce Weipa’s annual diesel consumption and its carbon dioxide emissions by around 1600 tons.” Manderson noted that the hybrid diesel/PV solution will introduce to the site a reliable source of electricity, with low maintenance requirements.

The project will have an initial capacity of 1.7 megawatts (MW) with the potential to expand by an additional 5 MW after the commissioning of the initial phase. The first phase of the project will generate sufficient electricity to offset up to 20 percent of the daytime electricity demand, while reducing the diesel consumption for every MWh of electricity produced.

“For the Weipa bauxite mine, solar PV complements the existing base-load generation by providing electricity in times of peak demand and reducing the amount of diesel fuel used,” said Jack Curtis, First Solar’s Vice President of Business Development for Asia Pacific. “First Solar is delighted to be working with Rio Tinto, ARENA and Ingenero on this landmark project that demonstrates how solar PV can be used to power the resources sector.”

“Our collaboration on the Weipa solar PV project is validation of the strength of our ongoing partnership with First Solar,” said Ingenero CEO Steve McRae. “Working together, we can provide the extensive project experience required for off-grid applications and draw on the PV module technology and utility scale experience provided by First Solar.”

With completion scheduled for late 2014, First Solar will supply its advanced thin-film PV modules and other balance of system components, in addition to providing operation and maintenance services for the duration of the project.

RTA will purchase the electricity under a 15 year Power Purchase Agreement. The project is one which all partners see as a step towards energy alternatives for remote mining operations.

About First Solar, Inc.

First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced module and system technology. The company’s integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar’s renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

About Rio Tinto Alcan

Rio Tinto Alcan is a global leader in the aluminum business and is one of five product groups operated by Rio Tinto, an international mining group. Rio Tinto Alcan’s Weipa bauxite mine is located on Western Cape York Peninsula. It is committed to sustainable development principles and continues to develop better ways of looking after the environment and partnering with its community stakeholders. For more information about Rio Tinto Alcan, please visit www.riotintoalcan.com.

About Ingenero

Ingenero is an Australian leader in the delivery of solar energy for commercial, industrial, utility and residential customers. Ingenero has simplified the way customers can lock in lower, long-term rates for electricity through innovative financial products such as solar leasing and Solar Power Purchase Agreements. Ingenero provides a wide range of solar implementation services including design, supply and installation of turnkey systems and ongoing monitoring and maintenance services. For more information about Ingenero, please visit www.ingenero.com.au.

About ARENA

ARENA was established by the Australian Government as an independent authority on 1 July 2012 to make renewable energy technologies more affordable and increase the amount of renewable energy used in Australia. ARENA is funded to 2022 to invest in renewable energy projects, support research and development activities, and increase industry and community knowledge about renewable energy. For more information about ARENA, please visit www.arena.gov.au.

For First Solar Investors

This release contains forward-looking statements which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements, among other things, concerning: our business strategy, including anticipated trends and developments in and management plans for our business and the markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, products, projected costs, warranties, solar module efficiency and balance of systems (“BoS”) cost reduction roadmaps, restructuring, product reliability and capital expenditures; our ability to continue to reduce the cost per watt of our solar modules; our ability to reduce the costs to construct photovoltaic (“PV”) solar power systems; research and development programs and our ability to improve the conversion efficiency of our solar modules; sales and marketing initiatives; and competition. These forward-looking statements are often characterized by the use of words such as “estimate, ” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “foresee,” “likely,” “may,” “should,” “goal,” “target,” “might,” “will,” “could,” “predict,” “continue” and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in Item 1A: “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports filed with the SEC.

Datacastle RED now available via IBM Cloud Marketplace

– See more at: http://www.datacastlecorp.com/site/press-releases/04282014—datacastle-brings-enterprise-endpoint-backup-to-the-ibm-cloud-platform.html#sthash.AJ53mfdq.dpuf

Sunshine Heart Appoints Kimberly Oleson as Senior Vice President, Clinical Affairs

EDEN PRAIRIE, Minn., April 28, 2014 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) today announced the appointment of Kimberly Oleson to the post of Senior Vice President, Clinical Affairs. In this capacity, Ms. Oleson will manage all aspects of the Company’s US pivotal study (COUNTER HF™) and EU post-market study (OPTIONS HF) for its flagship C-Pulse® Heart Assist System, a medical device addressing Class III and ambulatory Class IV heart failure.

“Kim brings to the Company deep expertise across all aspects of medical device trial enrollment and management. Having been involved with over 400 clinical trials in her career, it is a pleasure to welcome someone of Kim’s caliber to the Company and is a testament to the potential role the C-Pulse System will play in the treatment landscape for heart failure patients,” said Dave Rosa, Chief Executive Officer of Sunshine Heart.

Prior to joining Sunshine Heart, Ms. Oleson was Vice President of Global Clinical Operations at Medtronic, Inc. (NYSE:MDT), one of the world’s largest medical technology companies where she was the strategist responsible for building the company’s first centralized clinical operations organization serving Medtronic’s broad portfolio of clinical trials and developing contemporary methods related to total product lifecycle risk management and clinical trial risk management. Trained as a biostatistician, Ms. Oleson’s distinguished career includes positions of increasing responsibility across large and venture-based businesses within Medtronic, resulting in the global commercial release of multiple medical therapies in the fields of cardiology, interventional cardiology, cardiac electrophysiology, neurology and drug delivery. In addition to her clinical trial expertise, Ms. Oleson has co-authored 10 peer-reviewed publications and is credited with 4 issued/filed patents. She is an industry representative for regulatory standard technical committees including the International Standards Organization which published the ISO 14155:2011 Good Clinical Practice standard for medical device clinical trials. Ms. Oleson holds a B.A. in Biometry from the University of Minnesota.

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine^® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure.  Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions, expectations, and information currently available to management.  All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption “Risk Factors” and elsewhere in our filings with the SEC. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Company Reveals Aggressive Plans to Expand the Largest Shared Global Identity Network

San Jose, Calif. – March 27, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced that it has closed a Series E round of financing. Adams Street Partners led the investment round of $20 million in capital, with all existing ThreatMetrix institutional investors also participating in the investment.

In a 12-month period ending September 2013, investors poured more than$1.4 billion into the cybersecurity market, up 29 percent over the previous year. While many cybersecurity startups are in the early stages of business, ThreatMetrix has a proven business strategy and is uniquely positioned to protect online entities – including businesses, governments and individuals – through the ThreatMetrix™ Global Trust Intelligence Network (The Network). As the world’s largest identity network of shared intelligence, The Network enables companies and government agencies to share anonymized information across business boundaries to deliver the most comprehensive risk assessment in real time.

“ThreatMetrix has a trusted, compelling cybersecurity solution and extensive market traction that stand out compared to other unproven startups in the industry,” said Dave Welsh, Partner, Adams Street Partners. “The cybersecurity industry will only continue to grow in the coming years and ThreatMetrix offers comprehensive technology to protect against evolving risks. Given its already strong base of more than 2,500 customers, we are confident that this financing will position ThreatMetrix for further growth and success across industries and geographies.”

As part of the financing round, Welsh joins the ThreatMetrix board of directors. Welsh is a strategic fit as an investor as he has extensive experience in the cybersecurity industry and formerly served as the chief strategy officer at McAfee, the world’s largest dedicated security company. Adams Street Partners is also an investor in two of ThreatMetrix’s largest investors, USVP andAugust Capital, and has comprehensive working knowledge of ThreatMetrix and the market opportunity it is addressing.

“Adams Street Partners is an ideal fit to lead our latest round of financing, due to its expertise in the cybersecurity industry and familiarity with our existing investors,” said Reed Taussig, president and CEO, ThreatMetrix. “Today’s cybercriminals are more sophisticated than ever before and include talented, well-funded, international crime rings and nation states. This financing will enable us to expand the depth and breadth of The Network, grow our customer base and continuously build new capabilities into theTrustDefender™ Cybercrime Protection Platform to protect against rapidly evolving cyber threats.”

According to Taussig, the company will use the additional financing to continue its successful global expansion in context-based security and advanced fraud prevention. Specifically, the financing will enable ThreatMetrix to do the following:

• Broaden the reach of The Network, which currently analyzes more than 500 million transactions each month and protects over 160 million active user accounts across 2,500 customers and 10,000 websites. In today’s world, no company can stand alone in the fight against cybercriminals. The Network is a unique differentiator that offers all ThreatMetrix customers worldwide a collective approach to cybersecurity by enabling shared anonymized identity and threat data for real-time analysis of cybercrime risks.

• Build new capabilities in the TrustDefender Cybercrime Protection Platform – ThreatMetrix launched several breakthrough products and technologies in 2013, including ThreatMetrix™ Persona ID, ThreatMetrix™ Trust Tags and the ThreatMetrix™ Global Policy Engine. These capabilities substantially improve the ability to differentiate between trusted and criminal events and stay one step ahead of cybercriminals.

• Enhance its frictionless context-based authentication solutions, which enables enterprises to establish trust for each account login based on fully anonymous user identity, device usage, geolocation, behavior and other factors without compromising user identity or workforce efficiency. “As the bring-your-own-device (BYOD) trend accelerates, Gartner estimates that by year-end 2016, more than 30 percent of enterprises will use contextual authentication for remote workforce access.” [Source: Gartner Magic Quadrant for User Authentication, December, 2013]

• Increase mobile cybersecurity to protect the rising number of mobile transactions across industries. In 2013, mobile represented one-third of all transactions on The Network, and this number is projected to reach 50 percent by the end of 2014. ThreatMetrix recently reinforced its commitment to protect mobile computing by announcing an update that offers jailbreak detection and location-based authentication for mobile transactions.

• Expand into new markets, including enterprise security, healthcare, gaming and insurance in addition to the success it has already experienced in the financial service and e-commerce markets. Enterprise security professionals realize that incorporating fraud prevention tools to protect access to mission critical applications is vital to thwart hackers. During 2014 ThreatMetrix expects to make significant inroads into the traditional enterprise security market.

• Continue its expansion in European and Asian markets in addition to continued growth in North America.

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix™ Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

ThreatMetrix Augments Mobile Solution with Jailbreak Detection and Location-Based Authentication

San Jose, Calif. – March 13, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced the upcoming availability of the ThreatMetrix™ Spring 2014 Release, an extension to the company’s TrustDefender™ Cybercrime Protection Platform. This update delivers enhanced endpoint and context intelligence for mobile activity through a solution built on the ThreatMetrix™ Global Trust Intelligence Network (The Network).

Mobile devices represent an increasing number of transactions and account logins from consumers and across the workforce. In 2013, mobile represented one third of total traffic on The Network and this number is projected to reach 50 percent by the end of 2014. As mobile traffic and activities rise across industries, there are increased opportunities for cybercrime. Businesses must leverage advanced fraud prevention and context-based security to protect against cybercrime without compromising the intuitive user experience of mobile apps and browsers.

“Mobile device usage for e-commerce and banking will continue to rise and in order to prevent the associated risks, businesses must have the capabilities to effectively analyze mobile activity to detect returning authentic customers and device anomalies that indicate malicious behavior,” said Mustafa Rassiwala, senior director of product management, ThreatMetrix. “This includes differentiating between normal and jailbroken devices, as users with jailbroken devices are more likely to engage in criminal activity.”

With the Spring 2014 Release, The Network protects against mobile cybercrime using:

• Enhanced Mobile Identification: With the enhanced mobile software development kit (SDK), businesses can now detect jailbroken devices. This information often indicates that the mobile operating system has been breached and the security of all applications has been compromised. Cybercriminals typically jailbreak stolen mobile devices to gain full access to the original owner’s personal information. Additionally sophisticated attacks can remotely jailbreak end users’ mobile devices to set up Man-in-the-Middle attacks and easily compromise sensitive information – including social media, banking and e-commerce website logins.

• Mobile-Specific Context Information: GPS-based location detection enables businesses to implement geo-fencing and accept transactions only when end users are within a certain proximity of the approved location. For example, banks may want to restrict certain high risk activities such as adding new payments and money transfers on mobile devices only when the user is located within close proximity to their home address.

“By implementing enhanced location-based authentication capabilities and device recognition comprised of mobile jailbreak detection, identity, behavior and threat intelligence, businesses can establish trust for mobile activity without compromising user identity or convenience,” said Rassiwala. “ThreatMetrix analyzes each mobile activity such as user login or credit card purchase by combining intelligence from billions of previous transactions in The Network, the largest trusted identity network of shared intelligence, to provide businesses with the most comprehensive identity authentication solution on the market.”

With these new capabilities, ThreatMetrix has upped the ante in its fight against cybercrime and now offers comprehensive mobile protection with:

• Mobile SDK for Android and iOS to uniquely identify mobile devices

• Cookieless smart identification of devices when using mobile browsers

• Identity and account authentication using analytics that combine anonymized persona information, behavior and transaction context

“Businesses should rightfully focus on offering the best user experience on mobile apps without compromising on security and fraud prevention,” said Rassiwala. “Developers should not have to deal with low level device identification attributes that change periodically and ThreatMetrix regularly updates its mobile SDK leveraging the latest operating system enhancements to remain compliant and secure.”

The Network processes and analyzes more than 500 million monthly transactions, 160 million active user accounts, 2,500 customers and 10,000 websites. ThreatMetrix protects businesses across industries – including e-commerce, enterprises and financial services – against such threats as account takeover, payment fraud, fraudulent account registration and multi-channel Web fraud. Real-time analytics evaluate logins, payments and new account registrations for validity, enabling ThreatMetrix to authorize legitimate transactions and flag potential threats without negatively impacting the customer experience.

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix™ Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

Award Winners and Finalists Were Honored by Info Security Products Guide in San Francisco during the RSA Conference 2014 on February 24

San Jose, Calif. – February 27, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announces that Info Security Products Guide, the industry’s leading information security research and advisory guide, named the company a Bronze winner of the 2014 Global Excellence Awards for Most Innovative Company of the Year (Security). The security industry celebrated its 10th Annual 2014 Global Excellence Awards during the RSA Conference 2014 in San Francisco by honoring excellence in every facet of the industry, including companies, executives and products.

The award commemorates ThreatMetrix’s continuous innovation in the cybersecurity industry to help businesses combat the growing threat of cybercrime. ThreatMetrix has revolutionized the industry with the ThreatMetrix™ Global Trust Intelligence Network (The Network). Through The Network, ThreatMetrix offers protection against threats including account takeover, payment fraud, fraudulent account registration and multi-channel Web fraud.

“Recognition by the Info Security Products Guide exemplifies our dedication to creating cutting-edge solutions for context-based security and advanced fraud prevention to stay one step ahead of cybercriminals at all times,” said Bert Rankin, chief marketing officer, ThreatMetrix. “This industry honor validates our commitment to providing the highest level of online protection by utilizing the powerful reach of The Network, which enables anonymized global sharing of threat intelligence.”

The Network, the largest trusted identity network of shared intelligence, profiles tens of millions of users, devices and personas and processes more than 500 million login, payment and wire activities each month. Protecting and analyzing more than 160 million active user accounts, 2,500 customers and 10,000 websites, The Network differentiates between authentic and suspicious activity without compromising privacy or user experience.

For a full list of 2014 Global Excellence Awards winners, visit: http://www.infosecurityproductsguide.com/world/

About Info Security Products Guide

Info Security Products Guide sponsors leading conferences and expos worldwide and plays a vital role in keeping end-users informed of the choices they can make when it comes to protecting their digital resources. It is written expressly for those who are adamant on staying informed of security threats and the preventive measure they can take. You will discover a wealth of information in this guide including tomorrow’s technology today, best deployment scenarios, people and technologies shaping info security and market research that facilitate in making the most pertinent security decisions. The Info Security Products Guide Awards recognize and honor excellence in all areas of information security. To learn more, visit www.infosecurityproductsguide.com and stay secured.

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix™ Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

Context-Based Security and Advanced Fraud Prevention Provider Recognized for its Continuous Efforts to Build Trust on the Internet Leveraging the World’s Largest Trusted Identity Network

San Jose, Calif. – February 24, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announces it has been honored in two categories by the Cyber Defense Magazine Awards, including Most Innovative Anti-Malware Appliances Solution and Best Product Network Access Control Solution.

The Cyber Defense Magazine Awards recognize the top IT security leaders who strive to curate cutting-edge knowledge on cybercrime and create advanced solutions to solve the online security issues facing businesses today. The awards were announced during the RSA Conference 2014, held February 24-28 in San Francisco.

In conjunction with the conference, ThreatMetrix announced that it now offers frictionless context-based authentication for enterprise applications, which combines contextual information and user credentials to evaluate the risk of users attempting to access resources. This new offering provides several key benefits for enterprises, including frictionless access, increased security and operational efficiency.

“Our team is continuously developing new solutions to stay one step ahead of cybercriminals, and we’re thrilled to be honored by Cyber Defense Magazine in recognition of those efforts,” said Bert Rankin, chief marketing officer, ThreatMetrix. “We’re uniquely positioned to help companies prevent cybercrime as our trusted identity network is the largest in the world and protects more than 160 million active user accounts.”

ThreatMetrix was selected for the Cyber Defense Magazine Awards due to its anonymized global trusted identity network, the ThreatMetrix™ Global Trust Intelligence Network (The Network), which is used to differentiate between authentic and suspicious transactions and online activity. The Network is the most comprehensive global repository of identity and fraud data, protecting hundreds of millions of users and data points from cybercrime. Its real-time analytics evaluates logins, payments, new account registrations and remote access attempts for validity.

To learn more about ThreatMetrix’s context-based security and advanced fraud prevention solutions, visit ThreatMetrix at booth 232 in the South Hall this week at the RSA Conference 2014.

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix™ Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.